Clinical Trial Update: Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of MEDI-534 in infants 6 to <24 months with viral respiratory infections, including RSV and parainfluenza; completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parainfluenza Virus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• MEDI-534

Snippet

Sponsor: MedImmune LLC | Conditions: Respiratory Viral Infections, Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED | Results posted: 2012-04-09